Abstract library

20 results for "Prinzi".
#885 The Role of Combined 68Ga-DOTATOC and 18F-FDG PET/CT in Patients with Pancreatic Neuroendocrine Tumors
Introduction: The value of combined (68)Ga-DOTATOC (68Ga) and (18)F-FDG (18FDG) PET/CT in diagnosis and staging of pancreatic NET is still unclear.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Stefano Partelli
#937 Real-World Study on Everolimus in Advanced, Progressive Neuroendocrine Tumors
Introduction: Everolimus (EVE) is a valid therapeutic option for neuroendocrine tumors (NETs). However, data in the “real-world” setting outside regulatory trials are scant.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Francesco Panzuto
#955 Usefulness of the WHO Classification and of the ENETS TNM Staging System to Predict Prognosis in Patients with Rectal NENs
Introduction: WHO classification and TNM staging system have been proposed for rectal neuroendocrine neoplasia (NENs). However, their prognostic accuracy is not validated yet.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Gianfranco Delle Fave
#1088 Functional Imaging Tests versus Computed Tomography Scan: Detection of New Metastases and Clinical Usefulness in Digestive Neuroendocrine Neoplasms Follow-Up
Introduction: Digestive Neuroendocrine Neoplasms (DNENs) express in 80% of cases somatostatin receptors (SSTRs) detected by functional imaging tests (FITs). FITs are needed at diagnosis to define therapy but their role in follow-up (FU) is unclear
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Elettra Merola
Authors: Merola E, Panzuto F, Capurso G, Kump P, ...
#1103 Risk and Protective Factors for Midgut Carcinoid Tumours: A Case-Control Study of Prospectively Evaluated Patients
Introduction: The incidence of midgut carcinoid tumours is on the rise, but few studies have investigated risk factors for their occurrence.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Doctor Maria Rinzivillo
#1232 Prognostic Role of FDG-PET in Advanced Digestive Neuroendocrine Neoplasms
Introduction: The role of FDG-PET to predict clinical outcome in advanced digestive neuroendocrine neoplasms (dNENs) is still unclear
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Doctor Maria Rinzivillo
#1344 Reassessment of Proliferative Activity at Disease Progression in Neuroendocrine Neoplasms
Introduction: Ki67 is a key factor influencing prognosis and treatment in NENs. However, whether repeating histology at time of progression of disease (PD) is debated
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Dr. Francesco Panzuto
#1368 Everolimus in Pancreatic Neuroendocrine Carcinomas G3
Introduction: Neuroendocrine Carcinomas (NEC) G3 are heterogeneous diseases with different behaviors, basing on tumor morphology and Ki67 value. Platinum-based chemotherapy is considered the standard treatment in these pts. However, tumors with well-moderately differentiated morphology (NET G3), with Ki67 < 55% may be considered a separate entity in terms of prognosis and therapeutic options
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Francesco Panzuto
#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors
Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Prof. Rossana Berardi
#1725 Safety of Lanreotide 120 mg ATG (LAN) in Combination with Metformin (MET) in Patients (pts) with Progressive Advanced Well-Differentiated (WD) Gastro-Intestinal (GI) or Lung Carcinoids. A Pilot, One-Arm, Open-Label, Prospective Study: The MetNET-2 Trial
Introduction: Anti proliferative effect of LAN ATG 120 mg has been investigated in 204 GI-NET pts in Clarinet study with a 53% reduction in risk of death/progression vs placebo. An increasing number of trials have associated MET with better outcome in cancer pts due to a reduction of insulin/IGF1 levels and modulation of AMPK and TSC1-2/mTOR. The retrospective PRIME-net study conducted on 445 Italian pts, suggest that addition of MET to everolimus and/or SSA provides clinical benefit in diabetic pancreatic NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Sara Pusceddu
Authors: Prinzi N, Femia D, Concas L, Lo Russo G, ...
Keywords: lanreotide, metformin